Wuxi AppTec Co Ltd
Company Profile
Business description
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by China, Europe, and other regions.
Contact
288 Fute Zhong Road
Waigaoqiao Free Trade Zone
Pudong New Area
Shanghai200131
CHNT: +86 2150461111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
39,414
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,530.90 | 316.70 | -4.04% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,445.03 | 2,100.90 | -5.18% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,404.62 | 2,445.19 | -10.70% |
| NASDAQ | 15,604.17 | 946.44 | -5.72% |
| Nikkei 225 | 31,744.71 | 2,035.87 | -6.03% |
| NZX 50 Index | 11,833.52 | 391.76 | -3.20% |
| S&P 500 | 5,084.85 | 311.67 | -5.78% |
| S&P/ASX 200 | 7,356.40 | 311.40 | -4.06% |
| SSE Composite Index | 3,130.17 | 211.84 | -6.34% |